Symbiorph Biomedical Corporation Receives CE Mark Approval -- MEDICA - World Forum for Medicine


Symbiorph Biomedical Corporation

Symbiorph Biomedical Corporation Receives CE Mark Approval

Vancouver, Canada, October 10th, 2006 – Symbiorph Biomedical Corporation ( is pleased to announce that it has received CE mark approval for its Symflex™ Coronary Stent System, a novel stent system designed to treat coronary artery disease. Coronary artery stenosis or narrowing of the arteries that feed the heart muscle results in deterioration of heart function and can lead to serious complications such as valvular disease and ,if untreated, eventual death. This CE mark approval allows Symbiorph to begin selling the product throughout the member countries of the European Union.

The Symbiorph SYMFLEX™ Coronary Stent System incorporates a low profile balloon expandable stent designed for most types of coronary artery applications and a low profile catheter that provides superior deliverability for access to the more challenging side branch lesions. The stent incorporates off-set links between cells for superior flexibility and varied strut characteristics along the end crowns of the stent for enhanced implantation and visibility. The SYMFLEX™ Coronary Stent System is offered in diameters of 2.5mm, 3.0mm, 3.5mm, and 4.0mm. The lengths offered range from 9mm to 28 mm.

Symbiorph will be launching the SYMFLEX™ Coronary Stent System at its booth (Hall 16 Stand F41) at MEDICA; Europe’s largest medical device show. Symbiorph is presently arranging distribution for the SYMFLEX™ Coronary Stent System.

Symbiorph Biomedical Corporation is actively engaged in the development, marketing and distribution of minimally invasive medical device solutions for the exciting and rapidly growing fields of interventional cardiology, radiology, and endovascular medicine. Symbiorph’s first products are a family of high performance coronary stents and PTCA catheters. In addition to the SYMFLEX™ Coronary Stent System this product line will also include a cobalt chromium coronary stent and a new improved PTCA catheter expected for release in third and first quarter of 2007 respectively. Additional products are under development.

Symbiorph prides itself on developing unique, physician-driven products meeting the demands of everyday practice. The mission of the corporation is to develop and introduce medical products that provide short term palliative solutions while functioning synergistically with patient physiology to achieve long term rehabilitative corrective therapy.

For more information on the SYMFLEX™ Coronary Stent System or on Symbiorph Medical Systems please contact:

Symbiorph Biomedical Corporation
203-1099 West 8th Avenue
Vancouver, BC
Tel: 604-637-5727